acute myeloid leukemia

Targeting epigenetic modifiers and splicing regulators together may offer new acute myeloid leukemia treatment paths

by Sylvester Comprehensive Cancer Center edited by Sadie Harley, reviewed by Robert Egan  Editors’ notes Graphical summary of the results of our whole study. Credit: Science Advances (2026). DOI: 10.1126/sciadv.adu8292 Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic mutations—IDH2 and SRSF2—work cooperatively to mis-splice RNA messages and change […]

Targeting epigenetic modifiers and splicing regulators together may offer new acute myeloid leukemia treatment paths Read More »

Major treatment overhauls for acute myeloid leukemia

by Jennifer Welsh, University of Miami Leonard M. Miller School of Medicine edited by Sadie Harley, reviewed by Andrew Zinin  Editors’ notes Acute myelocytic leukemia (AML). Credit: Unsplash/CC0 Public Domain A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure

Major treatment overhauls for acute myeloid leukemia Read More »

Leukemia stem cell-based method aids relapse prediction in acute myeloid leukemia

by Lori Solomon edited by Gaby Clark, reviewed by Andrew Zinin   An assay that uses leukemia stem cells (LSCs) to assess measurable residual disease (MRD) outperforms traditional methods in patients with acute myeloid leukemia (AML), according to a study published online Aug. 23 in Bone Marrow Transplantation. Si-Qi Li, from the Peking University People’s Hospital in Beijing, and colleagues

Leukemia stem cell-based method aids relapse prediction in acute myeloid leukemia Read More »

Scroll to Top